Patents by Inventor Qibin Su

Qibin Su has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10961228
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: March 30, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Karl Magnus Nilsson, Annika Birgitta Margareta Astrand, Anna Ingrid Kristina Berggren, Johan R. Johansson, Matti Juhani Lepisto, Sameer Pralhad Kawatkar, Qibin Su, Jason Grant Kettle
  • Publication number: 20210078981
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 28, 2020
    Publication date: March 18, 2021
    Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Birgitta Margareta ASTRAND, Neil Patrick GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
  • Patent number: 10654835
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 19, 2020
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Birgitta Margareta Astrand, Neil Patrick Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K. Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
  • Publication number: 20190367490
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 5, 2019
    Applicant: AstraZeneca AB
    Inventors: Karl Magnus NILSSON, Annika Birgitta Margareta ASTRAND, Anna Ingrid Kristina BERGGREN, Johan R. JOHANSSON, Matti Juhani LEPISTO, Sameer Pralhad KAWATKAR, Qibin SU, Jason Grant KETTLE
  • Publication number: 20190092760
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 28, 2019
    Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
  • Patent number: 10167276
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: January 1, 2019
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Astrand, Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
  • Publication number: 20170320857
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 22, 2017
    Publication date: November 9, 2017
    Applicant: AstraZeneca AB
    Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
  • Patent number: 9714236
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 25, 2017
    Assignee: ASTRAZENECA AB
    Inventors: Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Qibin Su, Melissa Vasbinder, Claudio Edmundo Chuaqui
  • Publication number: 20170088543
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 30, 2017
    Applicant: AstraZeneca AB
    Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, Dedong WU, Wenzhan YANG, Tudor GRECU, James MCCABE
  • Publication number: 20150051185
    Abstract: The invention relates to chemical compounds of formula I, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: July 24, 2014
    Publication date: February 19, 2015
    Applicant: AstraZeneca AB
    Inventors: Leslie DAKIN, James Edward DOWLING, Michelle Laurae LAMB, Jon READ, Qibin SU, XiaoLan ZHENG
  • Publication number: 20110218182
    Abstract: The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: July 2, 2009
    Publication date: September 8, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Leslie Dakin, James Edward Dowling, Michelle Lamb, Jon Read, Qibin Su, Xiaolan Zheng
  • Publication number: 20110201628
    Abstract: The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.
    Type: Application
    Filed: September 29, 2009
    Publication date: August 18, 2011
    Inventors: Claudio Edmundo Chuaqui, Shan Huang, Stephanos Ioannidis, Jie Shi, Mei Su, Qibin Su
  • Publication number: 20100311748
    Abstract: The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and use of these compounds in the manufacture of medicaments for treating such diseases and medical conditions in a subject. Formula (IA) with the provisio that either R2 or R3 is (Z).
    Type: Application
    Filed: August 29, 2008
    Publication date: December 9, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Leslie Dakin, Benjamin Fauber, Alexander Hird, James Janetka, Daniel John Russell, Qibin Su, Bin Yang, Xiaolan Zheng
  • Publication number: 20100197749
    Abstract: The invention relates to chemical compounds of formula (I) and (II): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: January 15, 2007
    Publication date: August 5, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Scott Cowen, Tracey Deegan, Gurmit Grewal, Vibha Oza, Jamal Carlos Saeh, Qibin Su
  • Publication number: 20100029643
    Abstract: The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.
    Type: Application
    Filed: November 8, 2007
    Publication date: February 4, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Gurmit Grewal, Edward Hennessy, Victor Kamhi, Danyang Li, Paul Lyne, Vibha Oza, Jamal Carlos Saeh, Qibin Su, Bin Yang
  • Publication number: 20090111860
    Abstract: The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant vascularization or inflammatory component such as in tumor-related diseases. The present invention also relates to compounds that inhibit a5bl, and also that exhibit appropriate selectivity profile(s) against other integrins.
    Type: Application
    Filed: April 20, 2007
    Publication date: April 30, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Gurmit Grewal, Edward Hennessy, Victor Kamhi, Danyang Li, Vibha Oza, Jamal Carlos Saeh, Qibin Su
  • Publication number: 20090105324
    Abstract: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: April 20, 2007
    Publication date: April 23, 2009
    Applicant: AstraZeneca AB
    Inventors: Gurmit Grewal, Vibha Oza, Jamal Carlos Saeh, Qibin Su